Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial

Parvin Rahnama, Ali Montazeri, Hassan Fallah Huseini, Saeed Kianbakht, Mohsen Naseri, Parvin Rahnama, Ali Montazeri, Hassan Fallah Huseini, Saeed Kianbakht, Mohsen Naseri

Abstract

Background: Zingiber officinale R. rhizome (ginger) is a popular spice that has traditionally been used to combat the effects of various inflammatory diseases. The aim of this study was to evaluate the effects of ginger on pain relief in primary dysmenorrhea.

Method: This was a randomized, controlled trial. The study was based on a sample of one hundred and twenty students with moderate or severe primary dysmenorrhea. The students were all residents of the dormitories of Shahed University. They were randomly assigned into two equal groups, one for ginger and the other for placebo in two different treatment protocols with monthly intervals. The ginger and placebo groups in both protocols received 500 mg capsules of ginger root powder or placebo three times a day. In the first protocol ginger and placebo were given two days before the onset of the menstrual period and continued through the first three days of the menstrual period. In the second protocol ginger and placebo were given only for the first three days of the menstrual period. Severity of pain was determined by a verbal multidimensional scoring system and a visual analogue scale.

Results: There was no difference in the baseline characteristics of the two groups (placebo n = 46, ginger n = 56). The results of this study showed that there were significant differences in the severity of pain between ginger and placebo groups for protocol one (P = 0.015) and protocol two (P = 0.029). There was also significant difference in duration of pain between the two groups for protocol one (P = 0.017) but not for protocol two (P = 0.210).

Conclusion: Treatment of primary dysmenorrhea in students with ginger for 5 days had a statistically significant effect on relieving intensity and duration of pain.

Trial registration: IRCT201105266206N3.

Figures

Figure 1
Figure 1
A schematic view of sequences of ginger and placebo protocols.
Figure 2
Figure 2
The trial flowchart.

References

    1. Dawood MY. Primary dysmenorrhea: Advances in pathogenesis and management. Obstet Gynecol. 2006;108:428–441. doi: 10.1097/01.AOG.0000230214.26638.0c.
    1. Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire R. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther. 2002;24:1384. doi: 10.1016/S0149-2918(02)80043-1.
    1. Rosenwaks Z, Seegar-Jones G. Menstrual pain: its origin and pathogenesis. J Reprod Med. 1980;25:207–12.
    1. Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995;9:307–312. doi: 10.3109/09513599509160464.
    1. Edwards JE, Moore AR, Mcquay HJ. Rofecoxib for dysmenorroea: meta-analysis using individual patient data. BMC Womens Health. 2004;4:5. doi: 10.1186/1472-6874-4-5.
    1. Daniels SE, Torri S, Desjardins PJ. Valdecoxib for Treatment of Primary Dysmenorrhea, A Randomized, Double-blind Comparison with Placebo and Naproxen. J Gen Intern Med. 2005;20:62–67. doi: 10.1111/j.1525-1497.2004.30052.x.
    1. Zhu X, Proctor M, Bensoussan A, Smith CA, Wu E. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev. 2007;17 CD005288.
    1. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001. CD002124.
    1. Kikuzaki H, Nakatani N. Cyclic diarylheptanoids from rhizomes ofZingiber officinale. Phytochemistry. 1996;43:273–277. doi: 10.1016/0031-9422(96)00214-2.
    1. Schulick P. Ginger, common spice and wonder drug. 3. Brattleboro (VT): Herbal Free Press Ltd; 1996.
    1. Lee SH, Cekanova M, Baek SJ. Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog. 2008;47:197–208. doi: 10.1002/mc.20374.
    1. Pongrojpaw D, Somprasit C, Chanthasenanont A. A randomized comparison of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy. J Med Assoc Thai. 2007;90:1703–1709.
    1. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2011;20:1479–1489.
    1. Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, Leeprakobboon K, Leelasettagool C. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol. 2006;194:95–99. doi: 10.1016/j.ajog.2005.06.046.
    1. Haghighi M, Khalvat A, Toliat T, Jallaei S. Comparing the effects of ginger (zingiber officinale) extract and ibuprofen on patients with osteoarthritis. Arch Iran Med. 2005;8:267–271.
    1. Mustafa T, Srivastava KC, Jensen KB. Drug development: report 9. Pharmacology of ginger, Zingiber officinale. J Drug Dev. 1993;6:25–89.
    1. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F, Sandawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingeroles and diarylhepatanoids. Chem Pharm Bull (Tokyo) 1992;40:187–191.
    1. Ozgoli G, Goli M, Moattar F. Comparison of Effects of Ginger, Mefenamic Acid, and Ibuprofen on Pain in Women with Primary Dysmenorrhea. J Altern Complement Med. 2009;15:129–132. doi: 10.1089/acm.2008.0311.
    1. Grzanna R, Lindmark L, Frondoza CG. Ginger-An herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2005;8:125–132. doi: 10.1089/jmf.2005.8.125.
    1. Paula JAH. Benign diseases of female reproductive tract. 14. Philadelphia: Berek and Novak’s Gynecology, Lippincott William and Wilkins: Wolterrs Kluwer business; 2007. p. 446.
    1. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrheal. Am J Obstet Gynecol. 1982;144:655–660.
    1. Carlsson AM. Assessment of chronic pain. I. Aspects of the Reliability and Validity of the Visual Analogue Scale. Pain. 1983;16:87–101. doi: 10.1016/0304-3959(83)90088-X.
    1. Lee JS, Hobden E, Stiell IG, Wells GA. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med. 2003;10:1128–1130. doi: 10.1111/j.1553-2712.2003.tb00586.x.
    1. Dawood MY. Efficacy and safety of piroxicam-B-cyclodextrin (PBCD, Brexidol). Comparison studies with ibuprofen, naproxen sodium and placebo in the relief of moderate to severe abdominal pain associated with primary dysmenorrhea. The Brexidol Study Group. Today’s Therapeutic Trends. 1999;17:273–288.
    1. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998;105:780–9. doi: 10.1111/j.1471-0528.1998.tb10210.x.
    1. Morrison JC, Ling FW, Forman EK, Bates GW, Blake PG, Vecchin TJ, Linden CV, O’Connell MJ. Analgesic efficacy of ibuprofen for treatment of primary dysmenorrhea. South Med J. 1980;73:999–1002. doi: 10.1097/00007611-198008000-00014.
    1. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med. pp. 905–912.
    1. Traversa G, Walker A, Ippolito F, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Alegiani S, Raschetti R. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology. 1995;6:49–54. doi: 10.1097/00001648-199501000-00010.
    1. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879–888. doi: 10.1007/s00535-009-0102-2.
    1. Weidner MS, Sigwart K. Investigation of the teratogenic potential of Zingiber officinale extract in the rat. Reprod Tocicol. 2000;15:75–80. doi: 10.1016/S0890-6238(00)00116-7.
    1. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7. Philadelphia: Lippincott Williams and Wilkins; 2005.
    1. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinaleRoscoe): a review of recent research. Food Chem Toxicol. 2008;46:409–420. doi: 10.1016/j.fct.2007.09.085.
    1. Kim JK, Kim Y, Na KM, Surh YJ, Kim TY. [6]-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. Free Radic Res. 2007;41:603–614. doi: 10.1080/10715760701209896.
    1. Rahnama P, Falah Hossini H, Mohammadi K, Modares M, Khajavi Shojaei K, Askari M, Mozayani P. The effects of Zingiber Officional R on primary dysmenorrhea. J Med Plants. 2010;9:81–86.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever